miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 8, 2026

Kura Sushi outlines 16-unit expansion and 18% margin target for 2026 as cost management and pricing gains momentum

View original at seekingalpha.com
Kura Sushi outlines 16-unit expansion and 18% margin target for 2026 as cost management and pricing gains momentum Earnings Call Insights: Kura Sushi USA, Inc…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Company forecasts positive comps for Q2 supported by sequential improvements and easier comparisons

    80% confidence
  • 18% margin target already includes current pricing and labor initiatives

    80% confidence
  • Adoption of decoupled reservation system among rewards members was better than expected

    80% confidence
  • 10 restaurant units are under construction in addition to four openings to date, with goal of 16 new restaurant openings for the year

    80% confidence
  • Company expects to open one unit in fiscal Q2 and remainder to open in back half of the year

    80% confidence
  • Shelf registration is precautionary given strong liquidity position

    80% confidence
  • Q1 total sales were $73.5 million compared to $64.5 million in prior year period, with comparable restaurant sales of negative 2.5% consisting of negative 2.5% traffic and flat price/mix

    80% confidence
  • Total sales for fiscal Q1 was $73.5 million with comparable sales growth of negative 2.5%, outperforming comp expectations shared during last earnings call

    80% confidence
  • LTO Kura Reserve bacon sushi was a major traffic driver with IP tie-ins continuing to play significant role in performance

    80% confidence
  • Company has confidence in achieving flat to slightly positive comps for the full year

    80% confidence
  • Company is making great progress towards annual goals and achieving positive comparable sales on a full year basis

    80% confidence
  • Company reduced G&A as a percentage of sales by 80 basis points on an adjusted basis through aggressive cost management

    80% confidence
  • Dishwashing automation project remains on schedule with installations set for Q3

    80% confidence
  • Management feels very confident about Q2 comps and remains extremely confident about 18% full year margin target

    80% confidence
  • Company reaffirmed annual guidance for sales of $330-334 million, 16 new unit openings, G&A expenses of 12-12.5% of sales, and full year restaurant-level operating profit margin of approximately 18%

    80% confidence
  • Comp improvement attributed to both promotions and consumer trends

    80% confidence
  • Management absolutely expects positive comps in Q2

    80% confidence
  • Food cost benefits from tariff relief would take several months to materialize, and ending up at 30% food cost is something company is proud of given tariff headwinds

    80% confidence
  • No plans for additional price increases in fiscal 2026, November price adjustment is considered sufficient

    80% confidence
  • Renewed confidence in improving labor costs by 100 basis points in fiscal 2026

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com